	US 12,390,417 B2
	Praziquantel formulations
William Miller, Melbourne, FL (US)
Assigned to Villya LLC, Melbourne, FL (US)
Filed by Villya LLC, Melbourne, FL (US)
Filed on Jan. 25, 2022, as Appl. No. 17/583,738.
Application 17/583,738 is a continuation of application No. 16/991,397, filed on Aug. 12, 2020, abandoned.
Prior Publication US 2022/0142920 A1, May 12, 2022
Int. Cl. A61K 9/08 (2006.01); A61K 9/00 (2006.01); A61K 31/4985 (2006.01); A61K 47/10 (2017.01); A61K 47/26 (2006.01)

CPC A61K 9/08 (2013.01) [A61K 9/0095 (2013.01); A61K 31/4985 (2013.01); A61K 47/10 (2013.01); A61K 47/26 (2013.01)]

22 Claims

1. A liquid pharmaceutical formulation, comprising:

a. rubusoside; and

b. praziquantel, wherein the liquid formulation is prepared by steps comprising (i) dissolving rubusoside and praziquantel in ethanol to form a solution, (ii) evaporating the ethanol from the solution to form a dry mixture, and (iii) redissolving the dried mixture in water;

and wherein the rubusoside to praziquantel is in a molar ratio between 0.97:1 and 4.86:1.